Sanofi promises money back for discontinued blood disorder treatment – in some cases

Months after Pfizer launched its second drug warranty program, Sanofi is hopping on the trend.

The French pharma giant set up a warranty program for Cablivi, offering medical institutions a potential refund if inpatient treatment doesn’t work out. Patients must receive the drug in a hospital setting in order to qualify, and Sanofi will only cover the cost of up to six doses for patients who don’t respond, or up to 12 doses for those who worsen while on treatment.